These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 3359416)
1. Combined effects of bromovinyldeoxyuridine and fractionated or continuous administration of 5-fluorouracil in P388 leukemia-bearing mice. Keizer HJ; Pauwels R; Landuyt W; Balzarini J; van der Schueren E; De Clercq E Cancer Lett; 1988 Mar; 39(2):217-23. PubMed ID: 3359416 [TBL] [Abstract][Full Text] [Related]
2. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. Iigo M; Araki E; Nakajima Y; Hoshi A; De Clercq E Biochem Pharmacol; 1988 Apr; 37(8):1609-13. PubMed ID: 3358790 [TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal injection of dipyridamole increases the life span of tumor bearing mice treated with fluorouracil. Barberl-Heyob M; Merlin JL; Weber B In Vivo; 1992; 6(5):535-40. PubMed ID: 1457748 [TBL] [Abstract][Full Text] [Related]
4. Influence of molar ratio on the combination effect of 5-fluorouracil with guanosine 5'-monophosphate on P388 and L1210 leukemias. Iigo M; Hoshi A Eur J Cancer Clin Oncol; 1984 Mar; 20(3):411-5. PubMed ID: 6323189 [TBL] [Abstract][Full Text] [Related]
5. [Effects of combination chemotherapy of MCNU with various anti-cancer agents]. Machida S; Ito Y; Hoshino A Gan To Kagaku Ryoho; 1985 Feb; 12(2):298-302. PubMed ID: 3918506 [TBL] [Abstract][Full Text] [Related]
6. Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on life-span and 5-fluorouracil metabolism in mice with hepatic metastases. Iigo M; Nishikata K; Nakajima Y; Hoshi A; De Clercq E Eur J Cancer; 1990; 26(10):1089-92. PubMed ID: 2148885 [TBL] [Abstract][Full Text] [Related]
7. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. Iigo M; Nishikata K; Nakajima Y; Hoshi A; Okudaira N; Odagiri H; De Clercq E Biochem Pharmacol; 1989 Jun; 38(12):1885-9. PubMed ID: 2525905 [TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta. Borden EC; Sidky YA; Hatcher JF; Bryan GT Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000 [TBL] [Abstract][Full Text] [Related]
9. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Desgranges C; Razaka G; De Clercq E; Herdewijn P; Balzarini J; Drouillet F; Bricaud H Cancer Res; 1986 Mar; 46(3):1094-101. PubMed ID: 3943086 [TBL] [Abstract][Full Text] [Related]
10. Combination of anticancer agents with folic acid in the treatment of murine leukaemia P388. Parchure M; Ambaye RY; Gokhale SV Chemotherapy; 1984; 30(2):119-24. PubMed ID: 6697813 [TBL] [Abstract][Full Text] [Related]
11. Combination of 5-fluorouracil and cyclophosphamide in L1210 and P388 leukemias with changes in optimum treatments as a function of the age of the L1210 tumor at first treatment. Wampler GL; Carter WH; Campbell ED Cancer Invest; 1987; 5(6):523-33. PubMed ID: 3442730 [TBL] [Abstract][Full Text] [Related]
12. Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice. Iigo M; Miwa M; De Clercq E Jpn J Cancer Res; 1990 Apr; 81(4):431-5. PubMed ID: 2142152 [TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice. Fujimoto S Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525 [TBL] [Abstract][Full Text] [Related]
14. Potential of bromovinyldeoxyuridine in anticancer chemotherapy. De Clercq E Anticancer Res; 1986; 6(4):549-56. PubMed ID: 3752935 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of antitumor activity of 5-fluorouracil by ribothymidine. Tezuka M; Chiba Y; Okada S; Tamemasa O J Pharmacobiodyn; 1986 Aug; 9(8):683-7. PubMed ID: 3783412 [TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic index of cisplatin by procaine hydrochloride. Esposito M; Fulco RA; Collecchi P; Zicca A; Cadoni A; Merlo F; Rosso R; Sobrero A J Natl Cancer Inst; 1990 Apr; 82(8):677-84. PubMed ID: 2319610 [TBL] [Abstract][Full Text] [Related]
17. [Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil]. Shirasaka T; Shimamoto Y; Ohshimo H; Kimura A; Fukushima M Gan To Kagaku Ryoho; 1991 Mar; 18(3):403-9. PubMed ID: 2003740 [TBL] [Abstract][Full Text] [Related]
18. In vivo response of mitoxantrone and doxorubicin with dipyrone in parental and doxorubicin-resistant P388 leukemia. Kamath NS; Chitnis MP Oncology; 1990; 47(2):166-9. PubMed ID: 2314829 [TBL] [Abstract][Full Text] [Related]
19. Influence of concomitant infusion of thymidine and inosine on methotrexate activity in normal and P388-bearing mice. Uitendaal MP; Schornagel JH; Leyva A; Pinedo HM Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1527-32. PubMed ID: 6542016 [TBL] [Abstract][Full Text] [Related]
20. Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker. Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y Cancer Treat Rep; 1985 May; 69(5):523-5. PubMed ID: 4005874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]